Our Locations

Our site provides discovery synthesis for unnatural amino acids and peptide conjugates, from library screening to preclinical candidate selection. Our R&D labs offer custom synthesis for unnatural amino acids and other peptide building blocks, with over 2,500 catalog products available to accelerate your therapeutic development.

We also feature a high-potency R&D lab specifically designed to support peptide drug conjugate (PDC) discovery projects and other high-potency drug discovery research.

Our site specializes in discovery synthesis for oligonucleotides, amidites, and GalNAc, guiding projects from library screening to preclinical candidate selection. Our platform provides library, custom (nmol), and mid-scale (mmol) synthesis, covering all oligonucleotide types with dedicated analytical support.

Our capabilities include synthesizing siRNA, sgRNA, miRNA, DNA, ASO, PMO, aptamers, and isotopically labeled or modified oligonucleotides. In 2024, we synthesized over 45,900 oligonucleotides, including complex sequences up to 158 nucleotides, demonstrating our extensive experience.

Our site offers discovery synthesis for peptides and related synthetic conjugates, from library screening to preclinical candidate selection. In 2024, our platform supported over 500 global customers, delivering more than 41,000 peptides ranging from milligrams to kilograms.

Our expert teams support diverse peptide modalities, including long linear, cyclic, modified, PEGylated peptides, and peptidomimetics, helping accelerate your research programs.

We’re excited to announce our new 50-acre site, with Phase I operations beginning in 2027. This phase includes two API manufacturing plants for small molecules and one large-scale plant for oligonucleotides, peptides, and related synthetic conjugates.

Looking ahead, we plan to add at least four more plants, further expanding our capabilities across small molecule, oligonucleotide, and peptide manufacturing. This strategic expansion will significantly boost our capacity to support your drug development needs.

Our 169-acre Taixing site provides advanced intermediate and API manufacturing for both small molecules and TIDES (peptides, high potency APIs, and conjugates), from preclinical to commercial scales. We have nine plants with over 1,000 m³ reactor volume for small molecules and 12,000 L for peptide manufacturing.

The site includes a dedicated API plant with 10 production lines and a hydrogenation plant. Combining with our Changzhou site, our total solid-phase peptide synthesizer volume exceeds 41,000 L, with plans for further expansion. In 2025, our Taixing site successfully passed a US FDA pre-approval inspection for an innovative peptide drug.

At our Wuxi City site, we offer comprehensive drug product development and manufacturing, from preclinical to commercial stages, for both small molecules and TIDES (oligonucleotides, peptides, and conjugates). Our 12 plants handle a wide array of oral and parenteral dosage forms, including high-potency drugs.

Our R&D teams specialize in pre-formulation and formulation, accelerating your programs. We also provide lipid nanoparticle (LNP) development and manufacturing, leveraging multi-channel mixing technology for scalability. Our site has successfully passed numerous inspections by global regulatory bodies like the US FDA, EMA, China NMPA, and Brazil ANVISA.

At our 74-acre Changzhou campus, we offer API process development and manufacturing from preclinical to commercial stages for both small molecules and TIDES (oligonucleotides, peptides, and conjugates).

Our 15 plants include facilities for HPAPI, flow chemistry, and spray-dried dispersion, with over 1,800 m³ reactor volume.

We also house approximately 30 oligonucleotide and 20 peptide manufacturing lines. With Taixing, our total solid-phase peptide synthesizer volume exceeds 41,000 L. Our new R&D Center, strategically located nearby, expands our capabilities in advanced therapies. The Changzhou site has successfully passed numerous inspections by global regulatory bodies.

Our Jinshan site offers comprehensive API process development and manufacturing, from preclinical to commercial scales. We have five plants, including specialized facilities for HPAPI, enzyme fermentation, and flow chemistry, with a total reactor volume of nearly 400 m³.

We support various API enabling technologies like:

• Crystallization
• Particle engineering
• Biocatalysis
• Continuous manufacturing (flow chemistry)
• Chemo-catalysis
• Prep-HPLC & SFC & SMB.

Our site has successfully passed numerous inspections by global regulatory bodies, including the US FDA, EMA, China NMPA, Japan PMDA, South Korea MFDS, and Brazil ANVISA.

Providing comprehensive small molecule process development, spanning from preclinical stages to commercial manufacturing, as well as discovery synthesis for oligonucleotides and peptides. Waigaoqiao also offers small molecule and TIDES drug product research, development, and manufacturing services for oral and parenteral dosage forms, including:

• Solid-state development
• Pre-formulation
• Formulation
• Manufacturing
• Packaging
• Labeling
• Distribution

Our analytical teams support both API and drug product development from preclinical to commercial scales. The Waigaoqiao site has successfully cleared inspections by regulatory bodies such as the US FDA, China NMPA, Japan PMDA, and South Korea MFDS.

Our Couvet site currently manufactures oral drug products for eight countries, offering comprehensive manufacturing, packaging, and labeling services. Over the next 2-3 years, we plan to double our existing capacities.

We’ll also add injectable manufacturing lines, lipid nanoparticle (LNP) capabilities, and spray-dried dispersion, expanding our support to include new modalities like oligonucleotide and peptide drug products. Our site has successfully passed numerous inspections by the US FDA, Japan’s PMDA, and SwissMedic.

This site provides integrated early-phase CMC solutions in the US, offering process R&D and manufacturing for APIs and drug products for early clinical studies. Our analytical teams support both API and drug product development on-site, ensuring a seamless and efficient workflow.

Coming soon: our new 190-acre site is under Phase I construction to offer comprehensive formulation development and manufacturing. This facility will support both small molecule and TIDES (oligonucleotide, peptide, and conjugate) drug products from preclinical to commercial stages. Phase I is designed for oral and parenteral formulations, encompassing packaging, labeling, and distribution. This expansion will significantly enhance our capacity to meet diverse therapeutic needs.